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Abstract Vav is a hematopoietic cell-specific proto-oncogene. 
We show that interleukin-6 (IL-6) induces transient tyrosine 
phosphorylation of Vav in a human myeloma cell line, U266. A 
membrane-distal part of the cytoplasmic region of gpl30 is 
critical for association between Vav and gpl30, and the IL-6-
induced tyrosine phosphorylation of Vav. Mitogen-activated 
protein kinase (MAPK) (p42MAPK or extracellular signal-
regulated kinase 2 (Erk2)) is coprecipitated with Vav. MAPK 
activity in the anti-Vav immunoprecipitates is upregulated by IL-
6 stimulation. Furthermore Vav is associated with Grb2 which is 
known as an adapter protein leading to Ras activation. The 
results imply that Vav may link gpl30 activation to downstream 
MAPK activation in hematopoietic cells. 
Key words: Signal transduction; Tyrosine phosphorylation; 
Vav; gpl30 
1. Introduction 
Cytokines function initially through interaction with cell 
surface receptors, leading to activation of associated tyrosine 
kinases. These activated tyrosine kinases phosphorylate recep-
tors on their tyrosine residues, providing binding sites for the 
downstream intracellular molecules and inducing their activa-
tion. IL-6 is a pleiotropic cytokine and exerts its effects first by 
binding to its receptor (IL-6R) [1]. The IL-6/IL-6R complex 
subsequently interacts with the transmembrane signal trans-
ducing receptor component gpl30 [2], which results in homo-
dimerization and tyrosine phosphorylation of gpl30 [3]. gpl30 
is a common receptor component for IL-6-related cytokines 
like leukemia inhibitory factor, oncostatin M, ciliary neuro-
trophic factor, IL-11 and cardiotrophin-1 ([4] and references 
therein). We and others have observed that gpl30 recruits 
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multiple kinases and adapter proteins. For example, cytoplas-
mic tyrosine kinases in the Jak family are associated with 
gpl30 and are activated in response to IL-6 [5-7]. Moreover, 
IL-6 induces activation of MAPK [8], and gpl30 is known to 
be associated with Grb2, an adapter protein in the MAPK 
pathway [9]. Grb2 has been shown to bind constitutively to a 
guanine nucleotide exchange factor, Sos, which activates Ras 
by replacing GDP with GTP [10-12]. 
Vav has been observed as a substrate for receptor- and non-
receptor-tyrosine kinases and known to link activated cyto-
kine receptors to downstream effectors such as She, Grb2 and 
MAPK. Vav is a 95-kDa proto-oncogene product expressed 
exclusively in hematopoietic cells and trophoblasts [13,14]. 
Vav deficient mice showed that Vav is critical for proliferative 
response of T- and B-cells [15-17] and embryo development 
[14]. Vav undergoes tyrosine phosphorylation in response to 
ligation of antigen receptors on B- and T-cells [18-20], and 
stimulation by epidermal growth factor [20,21], IL-2 [22], steel 
factor [23], IL-3 and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) [24,25], G-CSF [26], erythropoietin 
(EPO) [27], interferon type I [28], and insulin [29]. Vav en-
codes an array of structural motifs including two Src homol-
ogy (SH) 3 domains, and one each of the SH2, Dbl-Cdc 24 
homology (DH) and pleckstrin homology domains 
[20,21,30,31]. The SH2 and SH3 domains of Vav have been 
reported to interact with She, Grb2, PI3K, GAP and tyrosine 
kinases including the Jak family and ZAP-70, which are all 
known to take part in cytokine signal transduction pathways 
[25,32-34]. 
In the current study using a human myeloma B-cell line 
U266, we demonstrate that IL-6 induces tyrosine phosphoryl-
ation of Vav, which requires the cytoplasmic region of gpl30. 
We further show that downstream signaling molecules such as 
Grb2 and Erk2 are associated with Vav, suggesting possible 
involvement of Vav in MAPK cascade in IL-6 signal trans-
duction. 
2. Materials and methods 
2.1. Cell culture 
The human myeloma B cell line U266 was cultured in RPMI 1640 
medium supplemented with 10% fetal calf serum (Gibco), penicillin 
(100 units/ml), streptomycin (100 μg/ml), and 5X10~5 M ß-mercap-
toethanol. Vaccinia virus infection of U266 cells was done as de-
scribed except that a poly-L-lysine (Sigma) coated dish was used to 
enhance the infection efficiency [3]. 
2.2. Antibodies and reagents 
Recombinant human IL-6 was kindly provided by Dr. K. Yasuka-
wa, Tosoh Corp. (Japan). Rabbit polyclonal antibodies to Vav and 
Erk2 as well as respective immunizing peptides were purchased from 
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Santa Cruz Biotechnology (USA). Mouse monoclonal anti-phospho-
tyrosine antibody was purchased from Upstate Biotechnology Inc. 
(USA), and mouse monoclonal anti-Erk2 antibody from Seikagaku 
Kogyo (Japan). Rabbit polyclonal anti-Grb2 antibody was prepared 
against a peptide corresponding to DPQEDGELGFRRGD. Mouse 
monoclonal anti-Grb2 antibody was kindly provided by Dr. J. Schles-
singer. Myelin basic protein (MBP) was purchased from Sigma, and 
[γ-32Ρ]ΑΤΡ (3000 Ci/mmol), BIOTRAK MAPK assay kit and en-
hanced chemiluminescence (ECL) kit from Amersham (USA). 
2.3. Immunoprecipitation and immunoblotting 
Cells were starved for 9-12 h in FCS-free RPMI 1640 and stimu-
lated with or without recombinant human IL-6 (0.5 μg/ml) at 37°C. 
The reaction was quenched by ice-cold lysis buffer (20 mM HEPES, 
0.5% (v/v) Brij 96, 10% glycerol, 1 mM EDTA, 150 mM NaCl, 10 
mM NaF, 0.5 mM Na3V04, 0.5 mM phenylmefhylsulfonyl fluoride, 
2 μg/ml aprotinin, pH 7.4). Cell lysates were collected after spinning 
at 15000 rpm for 15 min. Immune complexes with anti-Vav, -Erk2, 
-Grb2 and -gpl30 antibodies were precipitated with protein A-Sephar-
ose (Pharmacia), and washed with lysis buffer. Samples were subjected 
to SDS-PAGE and electrotransferred to ECL-nitrocellulose mem-
brane (Amersham). The immobilized proteins on the membrane 
were detected with the specific primary and secondary antibodies, 
and developed with the ECL kit according to the manufacturer's 
recommended procedure (Amersham). 
2.4. Preparation of glutathione S-transferase (GST) fusion proteins 
The pGEX-2T vector (Pharmacia) was used for overexpression of 
GST fusion proteins in Escherichia coli. GST-gpl30 fusion proteins 
were prepared as described [49]. Briefly, each fragment of gpl30 
cDNA encoding amino acids 620-692, amino acids 620-706 or amino 
acids 620-918 [35] was cloned into the EcoRI site of the pGEX-2T 
vector. GST fusion proteins were induced with 0.3 mM isopropyl ß-D-
thiogalactoside and purified on glutathione-Sepharose (Pharmacia). 
2.5. In vitro kinase assay 
The immunoprecipitates prepared as described above were further 
washed with kinase buffer (20 mM HEPES, 10 mM MgCl2, 5 mM 
MnCi2, pH 7.4), and incubated with MBP or synthetic peptide 
(MAPK assay kit, Amersham). Kinase reaction was performed in 
25 μΐ of kinase buffer containing 5 μθϊ of [γ-32Ρ]ΑΤΡ at 30°C for 
30 min. The 32P-labeled MBP was resolved by SDS-PAGE and visual-
ized by autoradiography. The labeled peptide was trapped on a bind-
ing paper (MAPK assay kit, Amersham) and the radioactivity was 
counted according to the manufacturer's recommended procedure. 
3. Results 
3.1. IL-6 stimulation induces rapid and transient tyrosine 
phosphorylation of Vav in U266 cells 
U266 is a human myeloma cell line and exhibits enhanced 
proliferation in the presence of IL-6 [36]. To examine involve-
ment of Vav in IL-6 signal transduction, U266 cells were 
Fig. 1. Identification of Vav phosphorylation on tyrosine. U266 
(6xl07/lane) were stimulated without or with IL-6 (0.5 μg/ml) for 
indicated periods. Cell lysates were immunoprecipitated (IP) with 
rabbit polyclonal anti-Vav antibody. The immunoprecipitates were 
analyzed by SDS-PAGE and immunoblotting (IB) with mouse 
monoclonal anti-phosphotyrosine antibody (anti-PY, upper panel). 
This blot was stripped and reprobed with mouse monoclonal anti-
Vav antibody (lower panel). 
Fig. 2. Association between Vav and gpl30. A: Schematic diagram 
of gpl30 constructs. GST was fused to the transmembrane domain 
(TM) and different numbers of amino acids in the cytoplasmic do-
main of gpl30. B: U266 (7xl07/lane) were stimulated without (—) 
or with (+) IL-6 (0.5 μg/ml) for 10 min and cell lysates were incu-
bated with GST or various GST-gpl30 fusion proteins. The purified 
GST fusion proteins with glutathione-Sepharose beads were sepa-
rated on SDS-PAGE and immunoblotted with monoclonal anti-Vav 
antibody. In the last two lanes, cell lysates were directly loaded 
onto SDS-PAGE. 
stimulated with IL-6 for varying periods. Cell lysates were 
subjected to precipitation with anti-Vav antibody and subse-
quent immunoblot with anti-phosphotyrosine antibody. Fig. 1 
(upper panel) shows that tyrosine phosphorylation of Vav 
occurred rapidly within 5 min after IL-6 stimulation and 
reached the maximum level at 10 min. It declined significantly 
after 30 min. Reblott ing the same membrane with anti-Vav 
antibody confirmed that a comparable amount of Vav was 
precipitated from IL-6-stimulated and non-stimulated cell ly-
sates (Fig. 1, lower panel). 
3.2. Vav is associated with the membrane-distal region of gpl30 
To examine whether Vav is associated with the cytoplasmic 
region of gpl30, we utilized various GST-human gpl30 fusion 
proteins designed according to its structural features [35]. 
These GST-gpl30 fusion proteins have either 51, 65 or 277 
cytoplasmic amino acids (GST-IC51, GST-IC65 and GST-
ICWT, respectively; see Fig. 2A). Lysates from cells stimu-
lated with or without IL-6 were incubated with these fusion 
proteins, and then the absorbents with glutathione beads were 
analyzed by SDS-PAGE and immunoblotted with anti-Vav 
antibody. As seen in Fig. 2B, GST-ICWT, which contains 
the entire cytoplasmic region of gpl30, showed constitutive 
binding with Vav. However, GST-IC65, which contains 
boxl and box2 but no further membrane-distal region, did 
not. This blot was reprobed with ant i-GST antibody and 
the amounts of GST and GST-gpl30 fusion proteins were 
found to be compatible (data not shown). 
Based on these results, IL-6-induced tyrosine phosphoryla-
tion of Vav was then examined in U266 cells expressing wild 
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type or truncated gpl30. U266 cells were transfected with 
vaccinia virus which encodes various human gpl30 con-
structs: Vac.WT expresses intact human gpl30. Vac.65 and 
Vac.51 are deletion mutants of gpl30, truncated just below 
box2 or boxl, respectively, just as GST-IC65 and GST-IC51 
(see Fig. 2A). All of the viral gpl30 proteins contain the entire 
extracellular and transmembrane regions of gpl30. The 
amount of viral gpl30 proteins was examined by precipitation 
and blotting with monoclonal anti-gpl30 antibody (Fig. 3A). 
Under this experimental condition, the expression of the en-
dogenous gpl30 was below the detection limit (see Mock 
lanes). In this system, tyrosine phosphorylation of Vav was 
only observed following IL-6 treatment of cells expressing 
Vac.WT, but not cells expressing the truncated mutants of 
gpl30. The immunoblotting with anti-Vav antibody showed 
a comparable amount of Vav protein present in all these U266 
transfectants (Fig. 3B). Taken together, the membrane-distal 
region of gpl30 is likely to be necessary for tyrosine phos-
phorylation of Vav in response to IL-6. 
Fig. 3. Requirement of a membrane-distal part of gpl30 for tyrosine 
phosphorylation of Vav. U266 cells (2X 106/lane) were infected with 
vaccinia virus (2X107) encoding entire or truncated gpl30 cDNAs. 
After incubation with virus for 16 h and following starvation for 
2 h, cells were stimulated without (—) or with (+) a combination of 
IL-6 (5 ng/ml) and soluble IL-6R (10 ng/ml) for 10 min. A: Cell ly-
sates were immunoprecipitated and immunoblotted with monoclonal 
anti-gpl30. B: The cell lysates were immunoprecipitated with poly-
clonal anti-Vav antibody and blotted with monoclonal anti-PY anti-
body (upper panel). After stripping, this blot was reprobed with 
monoclonal anti-Vav antibody (lower panel). 
3.3. Erk2 is associated with Vav 
Phospho-amino acid assays of 32P-labeled Vav showed 
phosphorylation not only on tyrosine but also on serine resi-
dues [20,25]. Recently, experiments with prolactin-induced 
Vav revealed the increased phosphorylation of Vav on ser-
ine/threonine residues in Nb2, a rat T-cell lymphoma cell 
line [37]. These previous findings led us to consider a possible 
association of serine/threonine kinase with Vav. We examined 
whether Erk2 is associated with Vav. As shown in Fig. 4A, 
Erk2 was detected in anti-Vav immunoprecipitates from 
U266. The electrophoretic mobility of the Vav-associated 
Erk2 protein was shifted upwards when cells were stimulated 
with IL-6. The Erk2 with a slower migration was suggested to 
be phosphorylated Erk2. The inclusion of the immunizing 
peptide during the immunoprecipitation step resulted in the 
complete disappearance of Erk2, indicating that Erk2 was 
present specifically in the anti-Vav immunoprecipitates. 
Fig. 4. Coprecipitation of Vav with Erk2. U266 (7X 107/lane) were stimulated without (—) or with (+) IL-6 (0.5 μg/ml) for 10 min. A: Cell ly-
sates were immunoprecipitated with polyclonal anti-Vav antibody in the absence or presence of immunizing peptide (p) and were immuno-
blotted with monoclonal anti-Erk2 antibody. The upper and lower arrows indicate activated and ordinary Erk2, respectively [46]. B: The cell 
lysates were immuoprecipitated with polyclonal anti-Vav antibody or polyclonal anti-Erk2 antibody. The immunoprecipitates were subjected to 
immune-complex kinase assay with MBP. Phosphorylated MBP was visualized by autoradiography. To equalize radioactivity loaded onto SDS-
PAGE, 1/20 of the amount of phosphorylated MBP from anti-Erk2 antibody was loaded. C: The cell lysates were immuoprecipitated with 
polyclonal anti-Vav antibody or rabbit normal serum. The immunoprecipitates were incubated with MAPK-specific synthetic peptide (see Sec-
tion 2) and incorporated 32P was counted. 
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Fig. 5. Association of Grb2 with Vav and gpl30. U266 (7X107/ 
lane) were stimulated without (—) or with (+) IL-6 (0.5 μg/ml) for 
10 min. A: Cell lysates were immunoprecipitated with polyclonal 
anti-Vav antibody, polyclonal anti-Grb2 antibody or monoclonal 
anti-gpl30 antibody, as indicated. In the fifth lane, a Grb2 peptide 
(p) was included during the immunoprecipitation step. The immuno-
precipitates were analyzed by SDS-PAGE and immunoblotted with 
monoclonal anti-Grb2 antibody. B: The cell lysates were incubated 
with GST or various GST-gpl30 fusion proteins. Proteins bound to 
the fusion proteins were purified with glutathione-Sepharose beads, 
and analyzed by SDS-PAGE and immunoblotting with monoclonal 
anti-Grb2 antibody. In the last two lanes, cell lysates were directly 
loaded onto SDS-PAGE. 
Furthermore, we examined whether these anti-Vav immuno-
precipitates contain an activity which phosphorylates MAPK-
specific substrates. Following preparation of immunoprecipi-
tates of anti-Vav and anti-Erk2 from U266 cell lysates, these 
immunoprecipitates were incubated with MBP. As seen in 
Fig. 4B, anti-Vav and anti-Erk2 immunoprecipitates from 
IL-6-stimulated cells phosphorylated MBP to a greater extent 
than those from unstimulated cells. MBP phosphorylation 
was not observed when immunoprecipitation was done in 
the presence of respective immunizing peptide. Additionally 
we performed a kinase reaction with a synthetic peptide con-
taining the consensus phosphorylation sequence for MAPK. 
The immunoprecipitates of anti-Vav antibody and control 
rabbit normal serum were incubated with the synthetic pep-
tide. As shown in Fig. 4C, anti-Vav immunoprecipitates from 
the IL-6-stimulated cells contained significant MAPK activity. 
The activity in the anti-Vav immunoprecipitates from the non-
stimulated cells was as low as that of the normal serum im-
munoprecipitates. These results suggest that coprecipitation of 
Vav with Erk2 is specific. 
3.4. Vav is coprecipitated with Grb2 
SH2/SH3 domains of Vav have affinity for specific tyrosine-
containing motifs, and are also found to bind with other SH2/ 
SH3 containing molecules including She, p85-PI3K, GAP and 
Grb2 [32,33,38]. Grb2 is known as an adapter protein to link 
stimulation of receptor/non-receptor tyrosine kinases to acti-
vation of the Ras/MAPK cascade [10-12], and Grb2 is sug-
gested to be involved in IL-6 signal transduction [9]. We thus 
examined whether Vav is associated with Grb2. The anti-Vav 
immunoprecipitates from cell lysates were separated on SDS-
PAGE and blotted with anti-Grb2 antibody. Fig. 5A shows 
that Grb2 was associated with Vav regardless of the stimula-
tion by IL-6. Grb2 was detected in the immunoprecipitates of 
anti-gpl30, which is in agreement with recent data by Kumar 
et al. [9] who showed that Grb2 associates with gpl30. Sub-
sequently we tested GST-gpl30 fusion proteins to determine 
which part of the cytoplasmic domain of gpl30 is responsible 
for Grb2 binding. Various GST-gpl30 fusion proteins as in 
Fig. 2A were incubated with stimulated or non-stimulated 
U266 cell lysates. The eluates from glutathione beads were 
analyzed by SDS-PAGE and immunoblotted with anti-Grb2 
antibody. Corresponding with the result in Fig. 2B, Grb2 was 
bound with GST-ICWT, but neither with GST-IC65 nor with 
GST-IC51. 
4. Discussion 
In the current study we determined that Vav was activated 
in response to IL-6 and transiently phosphorylated on tyro-
sine residues in U266 cells. Recent studies have demonstrated 
that tyrosine motifs in gpl30 and cytoplasmic subdomains like 
boxl, box2 and box3 of gpl30 are responsible for recruitment 
and/or activation of different cytoplasmic signaling compo-
nents. For example, association of Jakl, Jak2 and Tyk2 re-
quires the membrane-proximally located boxl in gpl30, and 
APRF/STAT3 requires the YXXQ motif located in the mem-
brane-distal region of gpl30, including box3 [39,40]. From the 
studies using mutants of gpl30, we suggest that the cytoplas-
mic subdomain of gpl30 required for tyrosine phosphoryla-
tion of Jak family kinase (i.e. boxl and box2) [7] may not be 
sufficient for tyrosine phosphorylation of Vav (Fig. 3B). It will 
be important to determine which subdomain in the mem-
brane-distal part (including box3) of gpl30 is related to tyr-
osine phosphorylation of Vav and what mechanisms are re-
sponsible for this, since most of the phosphorylated tyrosine 
residues in response to IL-6 are located in the membrane-dis-
tal part of gpl30. In the case of EPO receptor (although this 
molecule does not show box3 homology), the truncated form 
of EPO receptor retaining boxl and box2 as well as mem-
brane-distal extra ~ 70 amino acids in the cytoplasmic region 
is capable of mediating tyrosine phosphorylation of Vav in 
response to EPO [27]. 
Grb2 is an adapter protein to link receptors to the Ras/ 
MAPK pathway via association with Sos or Cdc25. By using 
a yeast two-hybrid system it was detected that a C-terminal 
SH3 domain of Grb2 binds to the N-terminal SH3 domain of 
Vav [33]. The linkage between tyrosine-phosphorylated recep-
tor and Grb2 was explained by the formation of a triple 
complex, Shc-Grb2-Vav [32]. The results in our present study 
and also of others showed that Grb2 is associated with gpl30 
[9]. Consequently our finding that Vav binds to Grb2 in U266 
predicts that Vav may lie between gpl30 and Ras/MAPK 
pathway. As seen in Fig. 5, the association of Vav with 
Grb2 existed regardless of IL-6 stimulation. Thus, IL-6 stimu-
lation may further modify or activate a component in this 
Ras/MAPK pathway for its full activation. 
Several reports have shown that Vav activates GDP/GTP 
exchange of Ras [19,37,41-43]. Although it is still controver-
sial whether Vav functions to accelerate directly the GDP/ 
GTP exchange in the Ras protein [44], Vav and Ras transfor-
mations activate common effectors like c-Myc or Erk2 [45,46]. 
Interestingly the GDP/GTP exchange factors Dbl and Sos 
show their serine phosphorylation. For example, the oncogene 
Dbl, whose DH domain is distantly related to that of Vav, 
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shows serine phosphorylation [47]. Sos was reported to be 
phosphorylated by downstream kinase of M E K [48]. In our 
results Erk2 is coprecipitated with anti-Vav immunoprecipi-
tates, but it remains to be tested using recombinant molecules 
whether Vav is directly phosphorylated by Erk2 in response to 
IL-6 stimulation. 
Proto-oncogenes which lie upstream of Raf /MAPK are 
known to be critical regulators in cell growth and differentia-
tion. In this sense Vav is an interesting molecule because it 
might link to the Raf /MAPK pathway. Further studies should 
focus on how Vav exactly contributes to Erk2 activation and 
how Vav plays a role in exerting the biological function of IL-
6. 
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